Radiotherapy Market - Global Forecast 2025-2032

The radiotherapy market is transforming oncology care by combining precision medicine, advanced technologies, and strategic responses to global challenges, redefining how cancer treatment is delivered and managed.

Radiotherapy Market Snapshot: Growth Trajectory and Key Metrics

The radiotherapy market grew from USD 7.75 billion in 2024 to USD 8.25 billion in 2025. It is expected to continue expanding at a CAGR of 6.77%, reaching USD 13.09 billion by 2032. This sustained growth reflects increasing cancer incidence, ongoing innovation in treatment technologies, and rising demand worldwide. Market evolution is driven by both technological advancements and regional diversification, creating opportunities for stakeholders at every level. Strategic investments in imaging systems, adaptive therapies, and AI-enabled solutions are unlocking new efficiencies and elevating standards of care globally.

Scope & Segmentation of the Global Radiotherapy Ecosystem

• Component: Hardware (Brachytherapy Afterloaders, Gamma Knife Systems, Imaging & Guidance Systems, Linear Accelerators (LINACs), Multileaf Collimators (MLCs), Proton Therapy Systems), Service (Maintenance & Calibration, Training & Consulting), and Software (Dose Calculation, Patient Workflow Systems, Treatment Planning).
• Radiotherapy Type: Brachytherapy, External Beam Radiotherapy (3D Conformal, Image-Guided, Intensity-Modulated, MR-guided, Proton Beam, Stereotactic Body, Stereotactic Radiosurgery, TomoTherapy, Volumetric Modulated Arc), and Systemic Radiotherapy (Radioimmunotherapy, Radiopharmaceutical-based, Targeted Alpha Therapy).
• Technology: Advanced Radiotherapy (Image-guided, Particle Therapy including Carbon-ion, Neutron, Proton), and Conventional Radiotherapy.
• Application: Brain Tumors, Breast Cancer, Cervical Cancer, Colorectal Cancer, Gastrointestinal Cancer, Head & Neck Cancer, Liver Cancer, Lung Cancer, Prostate Cancer, Spine Cancer.
• End User: Advanced Radio Oncology Centers, Hospitals, Oncology Clinics.
• Regions: Americas (United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe, Middle East & Africa (UK, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland, UAE, Saudi Arabia, Qatar, Turkey, Israel, South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan).
• Key Players Profiled: Accuray Incorporated, Agilent Technologies Inc., Cardinal Health, Charles River Laboratories, Elekta AB, GE HealthCare Technologies, IBA Dosimetry, IntraOp Medical, Koninklijke Philips, Leo Cancer Care, Mevion Medical Systems, Panacea Medical Technologies, Revvity, Epsilon Elektronik by BOZLU HOLDING, Siemens AG, ZEISS Group, Canon Medical Systems, Hitachi, ViewRay Technologies, BEBIG Medical, Vision RT, Toshiba Corporation, Mitsubishi Electric, RefleXion Medical, Sumitomo Heavy Industries.

Key Takeaways for Senior Decision-Makers

• The integration of advanced imaging, precision dosing, and artificial intelligence is increasing quality and efficiency across clinical workflows.
• Personalized medicine is increasingly shaping protocols, with genomic and biomarker-driven approaches aligning therapies with individual patient profiles and tumor behavior.
• Innovative delivery techniques such as hypofractionation and stereotactic systems are enhancing patient outcomes, reducing treatment visits, and optimizing resource allocation.
• The competitive landscape is marked by strategic alliances, technology acquisitions, and regional manufacturing shifts aimed at navigating regulatory complexities and market diversification.
• Ongoing education, workforce training, and digital health integration are essential for maximizing the impact of new systems and sustaining value creation.
• Addressing supply chain risks remains a priority, particularly as global events and trade dynamics influence equipment procurement and technology adoption strategies.

Tariff Impact: Navigating New U.S. Trade Realities

New tariff frameworks in the United States in 2025 are influencing radiotherapy supply chains by increasing import costs for key equipment and components. Stakeholders are adjusting sourcing strategies, localizing production, and scrutinizing vendor contracts to manage cost pressures. These shifts encourage both operational resilience and ongoing innovation, though they introduce challenges in quality assurance and market affordability, especially in tightly budgeted health systems.

Methodology & Data Sources

This report uses a multi-source approach, combining secondary research from journals, regulatory filings, and white papers with primary interviews of clinical oncologists, physicists, and procurement experts. Data were validated through triangulation, cross-checks, and ongoing monitoring of regulatory and technological changes. This method ensures that insights reflect current industry dynamics and emerging disruptors.

Why This Report Matters: Targeted Decision Support

• Equips executives with actionable intelligence on emerging technologies, segmentation trends, and competitive strategies relevant to immediate and future investment decisions.
• Enables confident navigation of regulatory shifts and trade policy events, supporting supply continuity and operational efficiency in a complex market environment.
• Supports the alignment of capital deployment with clinical priorities, patient outcomes, and regional expansion goals.

Conclusion: Guiding Strategic Innovation in Radiotherapy

By combining detailed segmentation analysis with practical insights into technology, trade, and competition, this report positions industry leaders to drive sustainable growth and deliver value in the evolving oncology ecosystem.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.